Subject: Background Document
The American Association for Clinical Chemistry (AACC) welcomes the opportunity to provide
input to the World Health Organization (WHO) Strategic Advisory Group of Experts (SAGE) on
In Vitro Diagnostics (IVD) regarding its background document for the April 16-20, 2018
meeting to discuss the creation of a Model List of Essential In Vitro Diagnostics (EDL). AACC
supports the creation of this document and offers its assistance in drafting and disseminating the
EDL. The association is committed to ensuring that all persons, wherever they reside, have
access to the laboratory services they and their doctors require to achieve better patient
AACC is a global scientific and medical professional organization dedicated to clinical
laboratory science and its application to healthcare. The association has members in 110
countries residing in all regions of the world. AACC has worked diligently to assist its members
working in resource-limited nations. Since 2011, the association’s Global Lab Quality Initiative
(GLQI) has conducted educational programs to help laboratory professionals improve their skills
in 16 countries in the Latin American, Caribbean, and Asia-Pacific regions. Also through the
GLQI, AACC works to improve newborn screening across the globe through educational
activities and policy discussions. The association plans to continue expanding this effort in
AACC’s flagship journal, Clinical Chemistry, is the world’s leading peer-reviewed journal of
clinical laboratory medicine, and The Journal of Applied Laboratory Medicine provides more
practical guidance to laboratory professionals.
AACC’s Annual Scientific Meeting & Clinical Lab Expo draws 20,000 attendees each year. The
2018 meeting will feature a plenary talk on the concept of an EDL by Drs. Tim Amukele and
Lee Schroeder. Through its publications and educational vehicles, AACC can help disseminate
throughout the global laboratory medicine community.
AACC agrees with the WHO’s decision to include tuberculosis, malaria, HIV, and Hepatitis B
and C on the first EDL. Given that much of the work has already been done in identifying the
appropriate tests for these conditions, AACC encourages the SAGE IVD panel to consider
expanding the first list to include other critical health conditions/tests. AACC recommends that
SAGE IVD consider the following when creating and refining the EDL:
- AACC encourages WHO to develop a tiered approach for assigning and stratifying tests
on the EDL. The model should consider the cost of the test, its effectiveness, already established common practices in a region or country, and the ease of introducing the test
to the community.
- The association suggests that the committee consider the following test-specific criteria
when selecting the EDL assays:
- test platform/reagent storage requirements;
- sample collection, handling, and storage requirements;
- level of technical expertise required to run and interpret tests;
- knowledge and skill required to troubleshoot problems;
- the specificity and sensitivity (false negative and false positive rates) of the assay;
- any follow-up confirmatory testing requirements.
AACC strongly supports this initiative and offers expertise in the development of the EDL.
AACC hopes that knowledgeable clinical laboratory professionals are included on the SAGEIVD panel; if not, the association can suggest several candidates. In addition, AACC can be a
partner in the dissemination of the list and accompanying information and looks forward to
working with WHO and the panel on this important issue.
If you have any questions, please email Vince Stine, PhD, AACC’s Director of Government
Affairs, at email@example.com.
Dennis J. Dietzen, PhD, DABCC, FAACC